SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., trading under ticker BCYP, is a clinical-stage biopharmaceutical company that entered public markets through a de-SPAC merger with Big Cypress Acquisition Corp, a blank-check vehicle sponsored by Big Cypress Holdings that completed its IPO in 2020 targeting the healthcare and life sciences sector. The combined company focuses on the development of fully human polyclonal antibody therapeutics produced using genetically engineered cattle, operating within the biotechnology industry. The company filed an 8-K current report with the SEC on July 17, 2025, under accession number 0000950170-25-096645, fulfilling its ongoing Exchange Act disclosure obligations. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time SPAC data on BCYP and every active deal in the market.